Effects of Chinese, Japanese and Western tea on hepatic P450 enzyme activities in rats

N Niwattisaiwong1, X X Luo, P F Coville

  • 1Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok, Thailand.

Insights

Certain teas, like Earl Grey and Oolong, significantly alter liver cytochrome P450 (CYP) enzyme activity in rats. This suggests varied effects of tea consumption on carcinogen metabolism, warranting further anti-cancer research.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Toxicology
  • Nutritional Science

Background:

  • Green tea consumption is linked to cancer protection against dietary carcinogens.
  • Cytochrome P450 (CYP) enzymes are crucial for metabolizing many carcinogens.
  • The impact of different tea types on CYP enzyme activity remains largely uncharacterized.

Purpose of the Study:

  • To investigate the effects of four distinct teas on the catalytic activities of specific liver CYP enzymes.
  • To determine if tea consumption influences the metabolic pathways involved in carcinogen detoxification.

Main Methods:

  • Preparation of 2.5% tea solutions from Oolong, Japanese green, Earl Grey, and Jasmine teas.
  • Administration of tea solutions or water to female Wistar rats for 4 weeks.
  • Analysis of liver microsomes to determine the activity of CYP1A1, CYP1A2, CYP2D6, and CYP3A enzymes.

Main Results:

  • Oolong, Japanese green, and Earl Grey teas significantly increased CYP1A1 activity compared to controls.
  • Earl Grey tea notably elevated CYP2D6 activity, while Oolong and Earl Grey teas significantly enhanced CYP3A activity.
  • Jasmine and Japanese green teas showed no significant impact on CYP3A activity, and no tested tea altered CYP1A2 activity.

Conclusions:

  • Different tea varieties exert differential effects on liver CYP enzyme activities.
  • Specific teas, such as Earl Grey and Oolong, can modulate key enzymes involved in xenobiotic metabolism.
  • Further research is necessary to correlate these observed changes in CYP activity with tea's potential anti-carcinogenic properties.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...